Ga68DOTATATEGeneratorBasedQC

Ga-68 DOTATATE Generator Based QC

api radiopharmaceuticals nuclear-medicine ga-68 pet somatostatin-receptor neuroendocrine-tumours
Open selection

Ga-68 DOTATATE Generator Based QC — Quality control of Ga-68 DOTATATE based on generator

ℹ️ Utility checks critical parameters of Ga-68 DOTATATE:

  • Radiochemical purity (≥95%)
  • Free and colloidal Ga-68 (≤5% and <2%)
  • Ge-68 breakthrough (<0.001%) — CRITICAL!
  • Specific activity, pH, endotoxins, sterility

⚠️ CRITICAL: Ge-68 breakthrough (T½=271 days) creates long-term burden!

Ga-68 DOTATATE binds to somatostatin receptors (SSTR).

Free gallium accumulates in liver, masking metastases.

Usage

Ga68DOTATATEGeneratorBasedQC.exe → demo mode (console output)

Ga68DOTATATEGeneratorBasedQC.exe input.csv output.json → evaluate your data

Input format

BatchNumber,RadiochemicalPurityPercent,FreeGalliumPercent,ColloidalGalliumPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityMBq,RadionuclidicPurityPercent,Ge68BreakthroughPercent,Zn68ImpurityPercent

Example

GA68-DOTATATE-2026-001,98.5,1.0,0.5,30.0,4.5,150.0,10.0,0,1500.0,99.99,0.0005,0.0

— WHY IS THIS NEEDED?

Ga-68 DOTATATE is gold standard for PET diagnosis of neuroendocrine tumors (NETs).

  • Binds to somatostatin receptor subtypes (SSTR2, SSTR5).
  • Ga-68 is obtained from Ge-68/Ga-68 generator (Ge-68 half-life = 271 days).
  • Requires high radiochemical purity for specific tumor accumulation.
  • Generator method allows daily production without cyclotron.

⚠️ CRITICAL:

  • Radiochemical purity ≥95% — guarantee of specific binding to SSTR.
  • Free Ga-68 ≤5% — free ions accumulate in liver and bones.
  • Colloidal Ga-68 <2% — colloids are taken up by liver and spleen macrophages.
  • Ge-68 breakthrough <0.001% — Ge-68 is long-lived and creates unnecessary radiation burden.
  • Specific activity must be high for effective targeting.
  • pH 3.5-5.5 — optimal media for Ga-DOTATATE complex stability.
  • Residual solvents (ethanol from generator eluate) must be minimal (<500 ppm).
  • Endotoxins <175 EU/mL — standard for parenteral drugs.
  • Sterility — MANDATORY.

Key features

  • Strict control of Ge-68 breakthrough characteristic of generator method.
  • Separate accounting of free and colloidal gallium.
  • Specific activity assessment for effective receptor binding.
  • Compliance with GMP and Pharmacopoeia requirements for Ga-68 radiopharmaceuticals.
  • Comprehensive safety check (endotoxins, sterility, pH, solvents).

Critical parameters

  • Radiochemical purity: ≥95.0%
  • Free Ga-68: ≤5.0%
  • Colloidal Ga-68: <2.0%
  • Specific activity: ≥10.0 GBq/mg
  • Radionuclidic purity: ≥99.9%
  • Ge-68 breakthrough: <0.001%
  • Residual solvents: <500 ppm
  • pH: 3.5–5.5
  • Endotoxins: <175 EU/mL
  • Sterility: no growth

💡 Usage tips:

1. Radiochemical purity determined by TLC or HPLC.

2. Ge-68 breakthrough controlled by gamma spectrometry few days after elution (when Ga-68 decays).

3. Synthesis usually performed on automatic modules or manually using kits.

4. Generator eluate contains ethanol, which must be considered in residual solvent calculation.

5. Drug must be used within few hours due to short Ga-68 half-life (68 min).

⚠️ Note: Ga-68 DOTATATE is vital tool for NET diagnosis. Generator quality and synthesis process directly affect ability to detect small metastases. Ge-68 breakthrough is unique risk of generator systems requiring constant monitoring.

input.csv

BatchNumber,RadiochemicalPurityPercent,FreeGalliumPercent,ColloidalGalliumPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityMBq,RadionuclidicPurityPercent,Ge68BreakthroughPercent,Zn68ImpurityPercent
GA68-DOTATATE-2026-001,98.5,1.0,0.5,30.0,4.5,150.0,10.0,0,1500.0,99.99,0.0005,0.0
GA68-DOTATATE-2026-002,96.0,3.0,1.5,25.0,4.0,200.0,20.0,0,1200.0,99.95,0.0008,0.0
GA68-DOTATATE-2026-003,90.0,8.0,3.0,15.0,5.0,600.0,50.0,1,800.0,99.50,0.0020,0.0

URS & FS — user requirements and functional specification

URS — User Requirements Specification

  • The utility shall accept input.csv with these mandatory columns: BatchNumber, RadiochemicalPurityPercent, FreeGalliumPercent, ColloidalGalliumPercent, SpecificActivityGBq_per_mg, pH, ResidualSolventsPPM, EndotoxinsEU_per_mL, SterilityTest, ActivityMBq, RadionuclidicPurityPercent, Ge68BreakthroughPercent, Zn68ImpurityPercent.
  • Each row shall be processed as a separate batch or record identified by BatchNumber.
  • Before evaluation, the utility shall validate the CSV structure, mandatory values, numeric fields and allowed text values.
  • Rules and limits shall be applied to every parameter in the input row.
  • Critical violations identified in the supplied description shall set the record result to FAIL.
  • Each row shall receive an overall PASS, WARNING or FAIL status with the triggered rules.
  • An invalid row shall not receive PASS.
  • output.json shall contain source values, applied limits, individual check results and errors.
  • The same input and the same rule profile shall produce the same result.

FS — Functional Specification

  1. Run Ga68DOTATATEGeneratorBasedQC.exe in demonstration mode or with input.csv output.json arguments.
  2. Read UTF-8 CSV and verify the exact set of mandatory columns.
  3. Convert row values to numeric and text types.
  4. Apply the rules defined in the approved version or configuration profile.
  5. Generate individual check results and derive the overall status from the most severe violation.
  6. Write machine-readable output.json.
  7. Structural and type errors shall be reported explicitly and shall not be masked by a successful status.

Complete input.csv example

BatchNumber,RadiochemicalPurityPercent,FreeGalliumPercent,ColloidalGalliumPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityMBq,RadionuclidicPurityPercent,Ge68BreakthroughPercent,Zn68ImpurityPercent
GA68-DOTATATE-2026-001,98.5,1.0,0.5,30.0,4.5,150.0,10.0,0,1500.0,99.99,0.0005,0.0
GA68-DOTATATE-2026-002,96.0,3.0,1.5,25.0,4.0,200.0,20.0,0,1200.0,99.95,0.0008,0.0
GA68-DOTATATE-2026-003,90.0,8.0,3.0,15.0,5.0,600.0,50.0,1,800.0,99.50,0.0020,0.0

Purpose of the supplied test rows

  • The first row contains values consistent with the criteria stated in the supplied description.
  • The second row contains values closer to the limits or moderate deviations.
  • The third row contains clear deviations for negative-result testing.

Minimum output.json structure

{
  "utility": "Ga68DOTATATEGeneratorBasedQC",
  "source": "input.csv",
  "results": [
    {
      "batchNumber": "BATCH-001",
      "status": "PASS",
      "checks": [
        {
          "parameter": "ParameterName",
          "value": 0,
          "limit": "configured rule",
          "status": "PASS"
        }
      ],
      "errors": []
    }
  ]
}

Minimum OQ scenarios

  • Process the complete supplied input.csv.
  • Remove a mandatory column and confirm a contract error.
  • Provide text instead of a numeric value and confirm a type error.
  • Test values directly on the configured limits.
  • Repeat the run with the same input and confirm an identical result.

Before operational use

  • Reconcile rules and limits with the approved specification, methods and SOP.
  • Fix the executable version and rule-profile version.
  • Retain the source CSV together with the generated JSON.

Included in packages

Endocrinology QC Suite

QC package for endocrinology: thyroid, pituitary/peptide hormones, corticosteroids, sex hormones and selected metabolic medicines.

Open

PetRad QC Suite

A specialised utility package for radiopharmaceutical quality control: PET, SPECT, therapeutic radionuclides, generators and decay calculations.

Open

PetRad3: expanded PET/SPECT and radiopharmaceutical QC package

A curated suite for PET/SPECT radiopharmaceuticals, generator and cyclotron radionuclides, labelled compounds, radiochemical purity, breakthrough, sterility and endotoxin control.

Open

Radioligand & Theranostics Expansion QC Suite

Radioligand & Theranostics Expansion QC Suite: FUZKK utility package for CSV→JSON QC checks with EU-first limit priority.

Open

Radiology QC Suite

QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.

Open

Radiopharmaceutical Diagnostics and Therapy QC Suite

36 utilities for clinically oriented radiopharmaceutical and workflow quality control: PET/SPECT tracers, the Tc-99m renal workflow, PRRT, PSMA therapy, targeted alpha therapy, radioembolization, bone-pain palliation, immuno-PET and generator-based radionuclide control.

Open

RPH isotope family: Ga/Ge

Ga-67, Ga-68 and Ge-68: generator, radiolabelling, PET/SPECT and purity workflows.

Open

RPH organ/system: bone and musculoskeletal

Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.

Open

RPH organ/system: brain and CNS

Brain perfusion, dopamine transporter, amyloid/tau, receptor imaging and neurological SPECT/PET.

Open

RPH organ/system: endocrine, thyroid and NET

Radioiodine, thyroid/parathyroid, somatostatin receptor, MIBG and neuroendocrine workflows.

Open

RPH organ/system: hepatobiliary and GI

HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.

Open

RPH organ/system: oncology and theranostics

Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.

Open

RPH use case: radionuclide therapy and theranostics

Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.

Open

RPH workflow: generators and isotope purity

Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.

Open

RPH workflow: product release QC

Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.

Open

RPH workflow: stability, storage, decay and waste

Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.

Open

RPH workflow: synthesis, labelling and kit reconstitution

Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.

Open

RPH: combined radiopharmaceutical QC package

RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.

Open